Publications

Found 4 results
Filters: Author is H. Teng  [Clear All Filters]
2016
R. Q. Yang, Teng, H., Xu, X. H., Liu, S. Y., Wang, Y. H., Guo, F. J., Liu, X. J., Yang, R. Q., Teng, H., Xu, X. H., Liu, S. Y., Wang, Y. H., Guo, F. J., and Liu, X. J., “Microarray analysis of microRNA deregulation and angiogenesis-related proteins in endometriosis”, vol. 15, p. -, 2016.
R. Q. Yang, Teng, H., Xu, X. H., Liu, S. Y., Wang, Y. H., Guo, F. J., Liu, X. J., Yang, R. Q., Teng, H., Xu, X. H., Liu, S. Y., Wang, Y. H., Guo, F. J., and Liu, X. J., “Microarray analysis of microRNA deregulation and angiogenesis-related proteins in endometriosis”, vol. 15, p. -, 2016.
2014
L. M. Dong, Zhang, X. Y., Teng, H., Li, M. S., and Wang, P., “Meta-analysis demonstrates no association between XRCC1 Arg399Gln polymorphism and bladder cancer risk”, vol. 13, pp. 9976-9985, 2014.
2011
M. S. Li, Liu, J. L., Wu, Y., Wang, P., and Teng, H., “Meta-analysis demonstrates no association between p53 codon 72 polymorphism and prostate cancer risk”, vol. 10, pp. 2924-2933, 2011.
Coughlin SS and Hall IJ (2002). A review of genetic polymorphisms and prostate cancer risk. Ann. Epidemiol. 12: 182- 196. http://dx.doi.org/10.1016/S1047-2797(01)00310-6 Guimaraes DP and Hainaut P (2002). TP53: a key gene in human cancer. Biochimie 84: 83-93. http://dx.doi.org/10.1016/S0300-9084(01)01356-6 Henner WD, Evans AJ, Hough KM, Harris EL, et al. (2001). Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate 49: 263-266. http://dx.doi.org/10.1002/pros.10021 PMid:11746272 Higgins JP and Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat. Med. 21: 1539-1558. http://dx.doi.org/10.1002/sim.1186 PMid:12111919 Hollstein M, Sidransky D, Vogelstein B and Harris CC (1991). p53 mutations in human cancers. Science 253: 49-53. http://dx.doi.org/10.1126/science.1905840 PMid:1905840 Hsing AW and Chokkalingam AP (2006). Prostate cancer epidemiology. Front. Biosci. 11: 1388-1413. http://dx.doi.org/10.2741/1891 PMid:16368524 Huang SP, Wu WJ, Chang WS, Wu MT, et al. (2004). p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Canc. Epidemiol. Biomarkers Prev. 13: 2217-2224. PMid:15598783 Jemal A, Siegel R, Xu J and Ward E (2010). Cancer statistics, 2010. CA Cancer J. Clin. 60: 277-300. http://dx.doi.org/10.3322/caac.20073 PMid:20610543 Katkoori VR, Jia X, Shanmugam C, Wan W, et al. (2009). Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin. Cancer Res. 15: 2406-2416. http://dx.doi.org/10.1158/1078-0432.CCR-08-1719 PMid:19339276 Klug SJ, Ressing M, Koenig J, Abba MC, et al. (2009). TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol. 10: 772-784. http://dx.doi.org/10.1016/S1470-2045(09)70187-1 Leiros GJ, Galliano SR, Sember ME, Kahn T, et al. (2005). Detection of human papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinomas of patients from Argentina. BMC Urol. 5: 15. http://dx.doi.org/10.1186/1471-2490-5-15 PMid:16307686 PMCid:1314892 Lesko SM, Rosenberg L and Shapiro S (1996). Family history and prostate cancer risk. Am. J. Epidemiol. 144: 1041-1047. PMid:8942435 Levine AJ (1997). p53, the cellular gatekeeper for growth and division. Cell 88: 323-331. http://dx.doi.org/10.1016/S0092-8674(00)81871-1 Levine AJ, Momand J and Finlay CA (1991). The p53 tumour suppressor gene. Nature 351: 453-456. http://dx.doi.org/10.1038/351453a0 PMid:2046748 Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, et al. (2000). Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 343: 78-85. http://dx.doi.org/10.1056/NEJM200007133430201 PMid:10891514 Mechanic LE, Bowman ED, Welsh JA, Khan MA, et al. (2007). Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors. Cancer Epidemiol. Biomarkers Prev. 16: 214-222. http://dx.doi.org/10.1158/1055-9965.EPI-06-0790 Pegoraro RJ, Moodley M, Rom L, Chetty R, et al. (2003). P53 codon 72 polymorphism and BRCA 1 and 2 mutations in ovarian epithelial malignancies in black South Africans. Int. J. Gynecol. Cancer 13: 444-449. http://dx.doi.org/10.1046/j.1525-1438.2003.13333.x PMid:12911720 Peters JL, Sutton AJ, Jones DR, Abrams KR, et al. (2006). Comparison of two methods to detect publication bias in meta-analysis. JAMA 295: 676-680. http://dx.doi.org/10.1001/jama.295.6.676 PMid:16467236 Quinones LA, Irarrazabal CE, Rojas CR, Orellana CE, et al. (2006). Joint effect among p53, CYP1A1, GSTM1 polymorphism combinations and smoking on prostate cancer risk: an exploratory genotype-environment interaction study. Asian J. Androl. 8: 349-355. http://dx.doi.org/10.1111/j.1745-7262.2006.00135.x PMid:16625286 Ricks-Santi L, Mason T, Apprey V, Ahaghotu C, et al. (2010). p53 Pro72Arg polymorphism and prostate cancer in men of African descent. Prostate 70: 1739-1745. PMid:20593380 PMCid:3057117 Shepherd T, Tolbert D, Benedetti J, Macdonald J, et al. (2000). Alterations in exon 4 of the p53 gene in gastric carcinoma. Gastroenterology 118: 1039-1044. http://dx.doi.org/10.1016/S0016-5085(00)70356-8 Suzuki K, Matsui H, Ohtake N, Nakata S, et al. (2003). A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J. Biomed. Sci. 10: 430-435. http://dx.doi.org/10.1007/BF02256434 PMid:12824702 Tsai MH, Lin CD, Hsieh YY, Chang FC, et al. (2002). Prognostic significance of the proline form of p53 codon 72 polymorphism in nasopharyngeal carcinoma. Laryngoscope 112: 116-119. http://dx.doi.org/10.1097/00005537-200201000-00020 PMid:11802048 Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, et al. (2007). STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology 18: 805-835. http://dx.doi.org/10.1097/EDE.0b013e3181577511 PMid:18049195 Viechtbauer W (2007). Confidence intervals for the amount of heterogeneity in meta-analysis. Stat. Med. 26: 37-52. http://dx.doi.org/10.1002/sim.2514 PMid:16463355 Wang YC, Chen CY, Chen SK, Chang YY, et al. (1999). p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin. Cancer Res. 5: 129-134. PMid:9918210 Wu HC, Chang CH, Chen HY, Tsai FJ, et al. (2004). p53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer. Urol. Int. 73: 41-46. http://dx.doi.org/10.1159/000078803 PMid:15263792 Wu WJ, Kakehi Y, Habuchi T, Kinoshita H, et al. (1995). Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers. Jpn. J. Cancer Res. 86: 730-736. http://dx.doi.org/10.1111/j.1349-7006.1995.tb02461.x Zhou Y, Li N, Zhuang W, Liu GJ, et al. (2007). P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int. J. Cancer 121: 1481-1486. http://dx.doi.org/10.1002/ijc.22833 PMid:17546594 Zintzaras E and Ioannidis JP (2005). Heterogeneity testing in meta-analysis of genome searches. Genet. Epidemiol. 28: 123-137. http://dx.doi.org/10.1002/gepi.20048 PMid:15593093